From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Check-Up covers the health care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Friday's episode, health-care analyst David Williamson examines what seems on the surface like a radical shift for Bristol-Myers Squibb . The company has announced that it will discontinue drug discovery in the hepatitis-C, diabetes, and neurological disorder spaces. It will instead focus on a number of treatment areas, singling out immuno-oncology as the most important for the pharma's future.
David takes a close look at this major shift and the reasons behind it, analyzes the space that Bristol-Myers is focusing on going forward, and tells investors whether this move is really as radical as it seems.
Looking for biotech profits?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Bristol-Myers Squibb's Radical Transformation originally appeared on Fool.com.David Williamson owns shares of Merck. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.